Kidney fibrosis preclinical models
Renal fibrosis is a hallmark of chronic kidney disease (CKD) and a key contributor to progressive renal dysfunction. It is characterized by excessive extracellular matrix deposition, leading to scarring, loss of kidney function, and ultimately, end-stage renal disease. Despite its critical role in CKD, effective therapeutic interventions remain limited, making preclinical research essential for developing targeted treatments.
Discover our validated kidney fibrosis models and assays to accelerate and de-risk the preclinical development of antifibrotic therapies.
In vitro kidney fibrosis assay
We offer high-throughput and physiologically relevant cell-based assays to study kidney fibrosis mechanisms and drug responses:-
- Fibroblasts, podocytes, and tubular epithelial cells.
- TGF-β Induced Fibrosis Assays – Evaluate drug efficacy in modulating pro-fibrotic pathways.
- Co-Culture Systems – Mimicking the renal microenvironment for better predictability.
- High-Content Imaging & Biomarker Analysis – Automated quantification of fibrosis-related markers
In vivo kidney fibrosis models
Our validated in vivo kidney fibrosis models ensure high translational value for preclinical drug assessment:
- UUO (Unilateral Ureteral Obstruction) Model – A surgically induced mouse model widely used for its rapid and pronounced induction of tubulointerstitial fibrosis and inflammation. It is particularly suited for the fast screening of drug efficacy.
- Unilateral Ischemia reperfusion Model – A clinically relevant AKI-to-CKD model inducing tubular injury, inflammation, fibrosis, and progressive GFR decline. It is widely used to study disease mechanisms and assess therapies aimed at preserving kidney function.
- Adenine Diet-Induced CKD Model – A dietary rodent model that reproduces key features of human chronic kidney disease through oral adenine administration, producing rapid tubular injury, interstitial inflammation and progressive renal fibrosis.
- Biomarker & Histopathological Evaluations – A combined approach uses functional (GFR and serum), urinary, and inflammatory biomarkers with quantitative histopathology to evaluate kidney injury and fibrosis. Blinded scoring, image-based analyses, and molecular readouts (e.g., gene expression) provide a sensitive, multidimensional assessment of disease progression and drug effects on both fibrosis and kidney function.